Bozdoğan, ÖmerKaya, Salih TunçYaşar, SelçukBaş, Erçin ÇağdaşÖzarslan, Oğulcan TalatEkşioğlu, DidemErim, Firdevs2020-04-302020-04-3020161300-01521303-6092https://doi.org/10.3906/biy-1510-42https://hdl.handle.net/20.500.12684/4538YASAR, Selcuk/0000-0002-9677-8823; YASAR, SELCUK/0000-0002-9677-8823; Yasar, Selcuk/0000-0002-7529-9751; Ozarslan, Talat Ogulcan/0000-0002-2635-7011WOS: 000378689600019This study examined the effect of yohimbine alone and in combination with glibenclamide on ischemia and reperfusion-induced arrhythmias in diabetes. Six minutes of ischemia were produced in 1-week diabetic rats by ligation of the left coronary artery, and 6 min of reperfusion were produced by releasing the artery. A dose of 5 mg/kg of yohimbine and glibenclamide was administered for 7 days prior to the coronary ligation. The blood pressure, heart rate, and arrhythmia were determined from the recorded ECG during the 6 min of ischemia and reperfusion and then compared using a one-way ANOVA statistical program and the chi-square test. The score of arrhythmia calculated from the type and duration of arrhythmia decreased in the diabetic rats (3.5 +/- 1.69 in control, 1.7 +/- 0.81 in diabetes group). The arrhythmia score returned to the control value in the rats that were given a combination of yohimbine and glibenclamide (3 +/- 1.73). Yohimbine is used in the treatment of erectile dysfunction; glibenclamide is used as an antidiabetic drug in diabetic patients and may be a risk factor in the increase of ischemia reperfusion-induced arrhythmias.en10.3906/biy-1510-42info:eu-repo/semantics/openAccessIschemiareperfusionarrhythmiadiabetesglibenclamideyohimbineArticle404899905WOS:000378689600019Q2Q3